133 related articles for article (PubMed ID: 36878223)
1. A Bispecific Peptide-Polymer Conjugate Bridging Target-Effector Cells to Enhance Immunotherapy.
Zhang W; Li D; Xu X; Chen Y; Shi X; Pan Y; Yao S; Piao Y; Zhou Z; Slater NKH; Shen Y; Tang J
Adv Healthc Mater; 2023 Jul; 12(18):e2202977. PubMed ID: 36878223
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.
Gu CL; Zhu HX; Deng L; Meng XQ; Li K; Xu W; Zhao L; Liu YQ; Zhu ZP; Huang HM
Acta Pharmacol Sin; 2022 Mar; 43(3):672-680. PubMed ID: 33990766
[TBL] [Abstract][Full Text] [Related]
4. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.
Patrick TA; Kranz DM; Zachary JF; Roy EJ
Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136
[TBL] [Abstract][Full Text] [Related]
5. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
6. A bispecific, crosslinking lectibody activates cytotoxic T cells and induces cancer cell death.
Rosato F; Pasupuleti R; Tomisch J; Meléndez AV; Kolanovic D; Makshakova ON; Wiltschi B; Römer W
J Transl Med; 2022 Dec; 20(1):578. PubMed ID: 36494671
[TBL] [Abstract][Full Text] [Related]
7. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
8. A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties.
Zhao J; Jiang L; Yang H; Deng L; Meng X; Ding J; Yang S; Zhao L; Xu W; Wang X; Zhu Z; Huang H
MAbs; 2022; 14(1):2044435. PubMed ID: 35239451
[TBL] [Abstract][Full Text] [Related]
9. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
[TBL] [Abstract][Full Text] [Related]
10. Chemoenzymatic Synthesis of a Rhamnose-Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy.
Hong H; Lin H; Li D; Gong L; Zhou K; Li Y; Yu H; Zhao K; Shi J; Zhou Z; Huang Z; Wu Z
Angew Chem Int Ed Engl; 2022 Sep; 61(38):e202208773. PubMed ID: 35891606
[TBL] [Abstract][Full Text] [Related]
11. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
12. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.
Lu L; Zhang H; Zhou Y; Lin J; Gao W; Yang T; Jin J; Zhang L; Nagle DG; Zhang W; Wu Y; Chen H; Luan X
Theranostics; 2022; 12(7):3456-3473. PubMed ID: 35547769
[No Abstract] [Full Text] [Related]
13. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.
Shi N; Zhou Y; Liu Y; Zhang R; Jiang X; Ren C; Gao X; Luo L
Front Immunol; 2022; 13():1047610. PubMed ID: 36518768
[TBL] [Abstract][Full Text] [Related]
14. Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1.
Jacquot P; Muñoz-Garcia J; Fleury M; Cochonneau D; Gaussin R; Enouf E; Roze C; Ollivier E; Cinier M; Heymann D
Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189383
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
[TBL] [Abstract][Full Text] [Related]
16. CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism.
Medler J; Kucka K; Melo V; Zhang T; von Rotenhan S; Ulrich J; Bremer E; Hudecek M; Beilhack A; Wajant H
Theranostics; 2022; 12(4):1486-1499. PubMed ID: 35198053
[No Abstract] [Full Text] [Related]
17. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8
Tichet M; Wullschleger S; Chryplewicz A; Fournier N; Marcone R; Kauzlaric A; Homicsko K; Deak LC; Umaña P; Klein C; Hanahan D
Immunity; 2023 Jan; 56(1):162-179.e6. PubMed ID: 36630914
[TBL] [Abstract][Full Text] [Related]
18. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
19. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
20. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
